Quay Pharma has invested extensively in specialist isolation facilities at its headquarters in Deeside to support the development of potent drugs in a protective environment.
The isolation suites are temporary structures, assembled to GMP requirements, that provide a highly flexible solution for analytical testing, and the development and small-scale processing of new drugs. Each suite is built to Quay’s design specifications in order to handle the particular characteristics of the many different types of products and specialist projects that the company handles.
Depending on the complexity of the process, the suites can be designed with individual isolation units within the main suite which incorporate sealed connectors that allow product to be safely and securely passed from one section to the next. On completion of the project, the entire structure, together with all the protective clothing that has been used, is collapsed on itself for safe disposal.
“This is the ideal solution for our multi-product facility that also offers our clients a custom-designed facility each time to support their development work,” comments Quay CEO Maireadh Pedersen. …/
The availability of these isolation facilities will further enhance Quay’s extensive range of outsourcing services. The company has already constructed suites for anumber of projects including work on allergy treatments and cytotoxic drugs. The facilities will also support its growing work in live biotherapeutics.
